Engagement of SIRPα Inhibits Growth and Induces Programmed Cell Death in Acute Myeloid Leukemia Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Irandoust, Mahban ^a   Alvarez Zarate, Julian ^b   Hubeek, Isabelle ^a   van Beek, Ellen M ^b   Schornagel, Karin ^b   Broekhuizen, Aart J F ^a   Akyuz, Mercan ^a   van de Loosdrecht, Arjan A ^a   Delwel, Ruud ^c   Valk, Peter J ^c   Sonneveld, Edwin ^d   Kearns, Pamela ^e   Creutzig, Ursula ^f   Reinhardt, Dirk ^f   de Bont, Eveline S J M ^g   Coenen, Eva A ^h   van den Heuvel Eibrink, Marry M ^h   Zwaan, C Michel ^h   Kaspers, Gertjan J L ^a   Cloos, Jacqueline ^a   van den Berg, Timo K ^b   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Dutch Childhood Oncology Group DCOG   (Netherlands)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IMATINIB; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ED9; REGULATOR PROTEIN; RETROVIRUS VECTOR; SIGNAL REGULATORY PROTEIN ALPHA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA ISOLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHILD; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84872193254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052143     Document Type: Article

References (63)

1. Hann IM, Stevens RF, Goldstone AH, Rees JK, Wheatley K, et al. (1997) Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 89: 2311-2318.
2. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, et al. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98: 1302-1311.
3. Rowe JM, Neuberg D, Friedenberg W, Bennett JM, Paietta E, et al. (2004) A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 103: 479-485.
4. Kaspers GJ, Zwaan CM, (2007) Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 92: 1519-1532.
5. Ravindranath Y, (2003) Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 15: 23-35.
6. Hann IM, Webb DK, Gibson BE, Harrison CJ, (2004) MRC trials in childhood acute myeloid leukaemia. Ann Hematol 83 Suppl 1: S108-112.
7. Martens JH, Stunnenberg HG, (2010) The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett 584: 2662-2669.
8. Goyama S, Mulloy JC, (2011) Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects. Int J Hematol 94: 126-133.
9. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, et al. (2003) Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112: 1751-1761.
10. Adams S, van der Laan LJ, Vernon-Wilson E, Renardel de Lavalette C, Dopp EA, et al. (1998) Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol 161: 1853-1859.
11. Seiffert M, Cant C, Chen Z, Rappold I, Brugger W, et al. (1999) Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood 94: 3633-3643.
12. Fukunaga A, Nagai H, Noguchi T, Okazawa H, Matozaki T, et al. (2004) Src homology 2 domain-containing protein tyrosine phosphatase substrate 1 regulates the migration of Langerhans cells from the epidermis to draining lymph nodes. J Immunol 172: 4091-4099.
13. Han X, Sterling H, Chen Y, Saginario C, Brown EJ, et al. (2000) CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem 275: 37984-37992.
14. Saginario C, Sterling H, Beckers C, Kobayashi R, Solimena M, et al. (1998) MFR, a putative receptor mediating the fusion of macrophages. Mol Cell Biol 18: 6213-6223.
15. Jiang P, Lagenaur CF, Narayanan V, (1999) Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem 274: 559-562.
16. Brown EJ, Frazier WA, (2001) Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11: 130-135.
17. Barclay AN, Brown MH, (2006) The SIRP family of receptors and immune regulation. Nat Rev Immunol 6: 457-464.
18. Tsai RK, Discher DE, (2008) Inhibition of "self" engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol 180: 989-1003.
19. Chao MP, Majeti R, Weissman IL, (2012) Programmed cell removal: a new obstacle in the road to developing cancer. Nat Rev Cancer 12: 58-67.
20. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
21. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, et al. (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138: 271-285.
22. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, et al. (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71: 1374-1384.
23. Uno S, Kinoshita Y, Azuma Y, Tsunenari T, Yoshimura Y, et al. (2007) Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol Rep 17: 1189-1194.
24. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, et al. (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142: 699-713.
25. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, et al. (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A 106: 14016-14021.
26. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, et al. (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A.
27. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, et al. (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A.
28. Seiffert M, Brossart P, Cant C, Cella M, Colonna M, et al. (2001) Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood 97: 2741-2749.
29. Damoiseaux JG, Dopp EA, Neefjes JJ, Beelen RH, Dijkstra CD, (1989) Heterogeneity of macrophages in the rat evidenced by variability in determinants: two new anti-rat macrophage antibodies against a heterodimer of 160 and 95 kd (CD11/CD18). J Leukoc Biol 46: 556-564.
30. Hatherley D, Harlos K, Dunlop DC, Stuart DI, Barclay AN, (2007) The structure of the macrophage signal regulatory protein alpha (SIRPalpha) inhibitory receptor reveals a binding face reminiscent of that used by T cell receptors. J Biol Chem 282: 14567-14575.
31. Vernon-Wilson EF, Kee WJ, Willis AC, Barclay AN, Simmons DL, et al. (2000) CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur J Immunol 30: 2130-2137.
32. Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, et al. (2011) CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A 108: 18342-18347.
33. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk, van Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
34. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625.
35. Kaspers GJ, Veerman AJ, Pieters R, Broekema GJ, Huismans DR, et al. (1994) Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 70: 1047-1052.
36. Roos D, Voetman AA, (1986) Preparation and cryopreservation of cytoplasts from human phagocytes. Methods Enzymol 132: 250-257.
37. Heemskerk MH, Hooijberg E, Ruizendaal JJ, van der Weide MM, Kueter E, et al. (1999) Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells. Cell Immunol 195: 10-17.
38. Kinsella TM, Nolan GP, (1996) Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 7: 1405-1413.
39. Kaspers GJ, Zwaan CM, Pieters R, Veerman AJ, (1999) Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays. Adv Exp Med Biol 457: 415-421.
40. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
41. Hubeek I, Comijn EM, Van der Wilt CL, Merriman RL, Padron JM, et al. (2008) CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Oncol Rep 19: 1517-1523.
42. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, et al. (2011) Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica 96: 221-230.
43. Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, et al. (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112: 4193-4201.
44. Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, et al. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113: 3088-3091.
45. Nagahara M, Mimori K, Kataoka A, Ishii H, Tanaka F, et al. (2011) Correlated expression of CD47 and SIRPA in bone marrow and in peripheral blood predicts recurrence in breast cancer patients. Clin Cancer Res 16: 4625-4635.
46. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350: 1605-1616.
47. Warrell RP Jr, de The H, Wang ZY, Degos L, (1993) Acute promyelocytic leukemia. N Engl J Med 329: 177-189.
48. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, et al. (1990) All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 76: 1710-1717.
49. van Beek EM, Cochrane F, Barclay AN, van den Berg TK, (2005) Signal regulatory proteins in the immune system. J Immunol 175: 7781-7787.
50. Gozzini A, Santini V, (2005) Butyrates and decitabine cooperate to induce histone acetylation and granulocytic maturation of t(8;21) acute myeloid leukemia blasts. Ann Hematol 84 Suppl 1: 54-60.
51. Liu S, Klisovic RB, Vukosavljevic T, Yu J, Paschka P, et al. (2007) Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther 321: 953-960.
52. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J 20: 6969-6978.
53. Kircher B, Schumacher P, Petzer A, Hoflehner E, Haun M, et al. (2009) Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol 83: 48-56.
54. Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, et al. (2005) Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT- and phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways. Mol Cell Biol 25: 7181-7192.
55. Larizza L, Magnani I, Beghini A, (2005) The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 46: 247-255.
56. Galbaugh T, Feeney YB, Clevenger CV, (2010) Prolactin receptor-integrin cross-talk mediated by SIRPalpha in breast cancer cells. Mol Cancer Res 8: 1413-1424.
57. Carter BZ, Kornblau SM, Tsao T, Wang RY, Schober WD, et al. (2003) Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 102: 4179-4186.
58. Chao MP, Weissman IL, Majeti R, (2012) The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24: 1-8.
59. Isenberg JS, Maxhimer JB, Hyodo F, Pendrak ML, Ridnour LA, et al. (2008) Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury. Am J Pathol 173: 1100-1112.
60. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, Degraff WG, et al. (2009) Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 1: 3ra7.
61. Soto-Pantoja DR, Miller TW, Pendrak ML, Degraff WG, Sullivan C, et al. (2012) CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8.
62. de Vries HE, Hendriks JJ, Honing H, De Lavalette CR, van der Pol SM, et al. (2002) Signal-regulatory protein alpha-CD47 interactions are required for the transmigration of monocytes across cerebral endothelium. J Immunol 168: 5832-5839.
63. Olek A, Oswald J, Walter J, (1996) A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 24: 5064-5066.